WO2017135800A1 - Trail 및 cd를 발현하는 중간엽줄기세포 및 이의 용도 - Google Patents
Trail 및 cd를 발현하는 중간엽줄기세포 및 이의 용도 Download PDFInfo
- Publication number
- WO2017135800A1 WO2017135800A1 PCT/KR2017/001308 KR2017001308W WO2017135800A1 WO 2017135800 A1 WO2017135800 A1 WO 2017135800A1 KR 2017001308 W KR2017001308 W KR 2017001308W WO 2017135800 A1 WO2017135800 A1 WO 2017135800A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- protein
- cells
- trail
- cell
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1077—Pentosyltransferases (2.4.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/02—Pentosyltransferases (2.4.2)
- C12Y204/02009—Uracil phosphoribosyltransferase (2.4.2.9)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
- C12Y305/04001—Cytosine deaminase (3.5.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Definitions
- the present invention relates to a recombinant lentiviral vector comprising a gene encoding a TRAIL (TNF-related apoptosis-inducing ligand) protein and a cytosine deaminase (CD) protein, and a cell transfected with a lentiviral produced using the vector.
- TRAIL TNF-related apoptosis-inducing ligand
- CD cytosine deaminase
- MSCs Mesenchymal stem cells
- the MSC can be obtained relatively easily in various adult tissues such as bone marrow, umbilical cord blood, and fat.
- MSC has a property of moving to an inflammation or injury site, and thus has a great advantage as a delivery agent for delivering a therapeutic drug.
- immune cells such as T cells, B cells, dendritic cells and natural killer cells, it is possible to regulate the immune function of the human body.
- MSC has the advantage that it can be cultured relatively easily in vitro , and researches for using it as a cell therapy are being actively conducted.
- Korean Patent No. 1585032 discloses a cell therapy containing mesenchymal stem cells cultured in a hydrogel.
- This document provides a composition which can be directly administered by shortening the pretreatment process in the process of separating the mesenchymal stem cells for use as a cell therapeutic agent.
- it does not mention at all the problems of the mesenchymal stem cells as described above and a solution for solving them. Therefore, there is a need for a study on mesenchymal stem cells that can be usefully used as a cell therapy.
- An object of the present invention is to provide a recombinant lentivirus comprising a gene encoding a TRAIL protein and a CD protein and a host cell transfected with the recombinant lentivirus.
- Another object of the present invention is to provide a pharmaceutical composition comprising the recombinant lentivirus or a host cell.
- the present invention provides a recombinant lentiviral vector comprising a gene encoding a TRAIL protein and a CD protein.
- the present invention also provides a recombinant lentiviral comprising a gene encoding a TRAIL protein and a CD protein.
- the present invention also provides a host cell transfected with the recombinant lentivirus.
- the present invention also provides a pharmaceutical composition for preventing or treating cancer comprising the recombinant lentivirus as an active ingredient.
- the present invention provides a pharmaceutical composition for preventing or treating cancer comprising the host cell as an active ingredient.
- Host cells transfected with a recombinant lentivirus comprising a gene encoding a TRAIL protein and a CD protein of the present invention express TRAIL protein and CD protein and maintain a high cell proliferation rate.
- safety is high by inhibiting abnormal differentiation and blocking the possibility of tumor formation. Therefore, the lentiviral or host cell may be usefully used as a cell therapeutic agent.
- 1 is a graph comparing cell proliferation of immortalized and non-immortalized MSCs:
- imMSC immortalized MSC
- MSC unimmortalized MSC
- Y axis cumulative cell population doubling.
- FIG. 2 is a schematic of the construction of the gene construct inserted into the pBD-4 lentiviral vector:
- TRE promoter comprising tetracycline response elements
- TRAIL TNF-associated apoptosis-inducing ligand
- IRES internal ribosomal entry site
- CD CD protein
- Figure 3 compares the expression of surface antigen proteins CD90, CD44, CD105, CD73, etc., which are inherent in MSCs after genetic manipulation of BM-03 cell line, and the expression of surface antigen proteins of bone marrow-derived MSCs.
- Figure 4 confirms the multi-differentiation capacity after genetic manipulation of the BM-03 cell line, it was confirmed that the BM-03 cell line can be adipogenic, bone formation, and cartilage formation.
- Lane 1 is a marker
- lane 2 is a negative control
- lane 3 is a positive control
- lanes 4 to 6 represent BM-03.
- FIG. 6 is a graph confirming the expression of TRAIL protein by FACS according to the treatment of doxycycline (Dox).
- FIG. 7 is a graph showing 5FC treatment of mesenchymal stem cells expressing TRAIL protein and CD protein, thereby confirming cell death by FACS.
- Figure 9 shows the results of analyzing the karyotype of the gene-introduced cells for the BM-03 cell line.
- the present invention provides a recombinant lentiviral vector comprising a gene encoding a TRAIL protein and a CD protein.
- TRAIL apoptosis-inducing ligand
- the TRAIL is one of suicide genes and selectively induces apoptosis of transformed cells. Specifically, TRAIL activates an apoptosis signal transduction system by binding to apoptosis receptor-4 (DR-4), DR-5, decoy receptor or decoy receptor-2 present on the cell surface. TRAIL is not toxic to normal cells and is known to specifically induce apoptosis only in cancer cells.
- DR-4 apoptosis receptor-4
- DR-5 decoy receptor or decoy receptor-2
- TRAIL protein may be a protein of human origin.
- the TRAIL protein is present in the form of a homotrimer capable of binding to three receptors.
- the TRAIL protein of the invention may be a polypeptide having the amino acid sequence of SEQ ID NO: 1.
- the TRAIL protein may have at least about 70%, 80%, 90%, or 95% homology with the amino acid sequence of SEQ ID NO: 1.
- the gene encoding the TRAIL protein may be a polynucleotide having a nucleotide sequence of SEQ ID NO: 2.
- the nucleotide sequence encoding the TRAIL protein may have at least about 70%, 80%, 90% or 95% homology with the nucleotide sequence of SEQ ID NO: 2.
- CD protein is a cytosine deaminase protein
- CD and UPRT uracil phosphoribosyltransferase
- CD protein may be interchanged with “CD :: UPRT”.
- Cells expressing the CD protein convert 5FC (5-fluorocytosine) into 5FU (5-fluorouracil), which is highly cytotoxic, inducing apoptosis.
- 5FC 5-fluorocytosine
- 5FU 5-fluorouracil
- the sequence of the gene encoding the CD protein according to the present invention is the FCY1 gene encoding the CDase of Saccharomyces cerevisiae , and FUR ⁇ 1105 encoding the UPRTase which is deleted 35 amino acids from the N-terminus. Codon-optimized sequence of fusion genes. Such sequences may be those described in US Pat. No. 5,338,678, WO 96/16183, and WO 99/54481.
- the CD protein may be a polypeptide having an amino acid sequence of SEQ ID NO: 3.
- the CD protein may have at least about 70%, 80%, 90% or 95% homology with the amino acid sequence of SEQ ID NO.
- the gene encoding the CD protein may be a polynucleotide having a nucleotide sequence of SEQ ID NO: 4.
- the nucleotide sequence encoding the CD protein may have at least about 70%, 80%, 90% or 95% homology with the nucleotide sequence of SEQ ID NO.
- lentiviral vector is a type of retrovirus and is also referred to as a vector in the form of a single stranded RNA in combination with a lentiviral transfer vector.
- the lentiviral vector may be inserted into genomic DNA of a cell to be infected to stably express a gene, and may transfer the gene to dividing cells and non-dividing cells. Since the vector does not induce an immune response in the human body, expression is persistent.
- a gene of a large size can be delivered as compared to the adenovirus vector, which is a viral vector used in the prior art.
- the lentiviral vector may further include a gene encoding a thymidine kinase (TK) protein.
- the TK protein is an enzyme that catalyzes thymidylic acid production by binding phosphoric acid at the ⁇ position of ATP to thymidine, thereby transforming thymidine into triphosphate form. Modified thymidine cannot be used for DNA replication and is therefore known to induce death of cells comprising it.
- the TK protein can be used as long as it is a known sequence.
- the TK protein may be a polypeptide having an amino acid sequence of SEQ ID NO: 5.
- the gene encoding the TK protein may be a polynucleotide having a nucleotide sequence of SEQ ID NO: 6.
- the recombinant lentiviral vector of the invention may comprise one or two promoters.
- the promoter may be a cytomegalovirus (CMV), respiratory syncytial virus (RSV), human elongation factor-1 alpha (EF-1 ⁇ ) or tetracycline response elements (TRE) promoter.
- CMV cytomegalovirus
- RSV respiratory syncytial virus
- EF-1 ⁇ human elongation factor-1 alpha
- TRE tetracycline response elements
- the recombinant lentiviral vector can regulate the expression of TRAIL protein and CD protein by one promoter.
- the promoter may be operably linked to a gene encoding a protein to be expressed.
- the TRAIL protein and CD protein may be linked to a TRE promoter.
- the TRE promoter may activate transcription of a gene linked to a promoter by a ttracycline transactivator (tTA) protein.
- tTA ttracycline transactivator
- the tTA protein binds to the TRE promoter and activates transcription in the absence of tetracycline or doxycycline, and when present, does not bind to the TRE promoter and thus does not activate transcription.
- expression of TRAIL protein and CD protein can be regulated by the addition of tetracycline or doxycycline.
- operably linked means that a particular polynucleotide is linked to another polynucleotide so that it can function. That is, operably linked genes encoding a particular protein means that the gene is transcribed into mRNA and translated into the protein by the action of the promoter.
- an internal ribosome entry site may be included to express each protein from the one transcript.
- the "internal ribosome entry site” refers to a nucleic acid sequence that functions to allow translation from an intermediate site of the transcript instead of the 5'-cap structure in the process of protein synthesis in eukaryotes.
- IRES can be used to produce proteins that perform multiple different functions from one transcript.
- the recombinant lentiviral vector of the present invention may be linked to the TRAIL protein and CD protein by IRES and transcribed into one transcript, and then each protein may be produced therefrom.
- the present invention provides a recombinant lentiviral comprising a gene encoding a TRAIL protein and a CD protein.
- the recombinant lentiviral is transformed into a host cell with the lentiviral vector, packaging plasmid and envelope plasmid of the present invention; And separating the lentivirus from the transformed host cell.
- packaging plasmid and "envelope plasmid” refer to helper structures (eg, plasmids or isolation) for producing lentiviral from the lentiviral vectors of the present invention for efficient transfection.
- Nucleic acid Such constructs contain elements useful for preparing and packaging lentiviral vectors in host cells. Such elements include structural proteins such as gag precursors; processing proteins such as pol precursors; Proteases, envelope proteins, and expression and regulatory signals necessary for preparing proteins and producing lentiviral particles in host cells, and the like.
- the production of recombinant lentiviruses may include Lenti-X Lentiviral Expression System from Clontech Laboratories, a packaging plasmid from Addgene (eg, pRSV-Rev, psPAX, pCl-VSVG, pNHP, etc.) or envelope plasmid (eg, pMD2.G, pLTR-G, pHEF-VSVG, etc.) can be used.
- Addgene eg, pRSV-Rev, psPAX, pCl-VSVG, pNHP, etc.
- envelope plasmid eg, pMD2.G, pLTR-G, pHEF-VSVG, etc.
- the present invention also provides a host cell transfected with the recombinant lentivirus.
- transfection refers to the delivery of a gene loaded into a recombinant lentiviral vector via viral infection.
- Host cells are human embryonic stem cells (hES), bone marrow stem cells (bone marrow stem cells, BMSC), mesenchymal stem cells (MSC), human neural stem cells (human neural stem cells) stem cells, hNSC), limbal stem cells, or oral mucosal epithelial cells.
- the host cell may be a mesenchymal stem cell.
- MSC meenchymal stem cell
- chondrocytes a multipotent stromal cell that can differentiate into a variety of cells, including bone cells, chondrocytes and adipocytes.
- Mesenchymal stem cells can be differentiated into cells of specific organs such as bones, cartilage, fat, tendons, nerve tissues, fibroblasts and muscle cells. These cells can be isolated or purified from adipose tissue, bone marrow, peripheral nerve blood, umbilical cord blood, periosteum, dermis, mesoderm-derived tissue and the like.
- the host cell may be prepared by the following method:
- hTERT and c-myc are immortalized host cells.
- other genes known as immortalized genes may be used.
- the hTERT and c-myc protein may be a polypeptide having an amino acid sequence of SEQ ID NO: 9 and SEQ ID NO: 7, respectively.
- the genes encoding the hTERT and c-myc proteins may be polynucleotides having the nucleotide sequences of SEQ ID NO: 10 and SEQ ID NO: 8, respectively.
- tTA is a gene capable of controlling expression of a target protein, and means tetracycline transactivator.
- the Tet-off system used in the present invention can regulate the expression of the target protein depending on the presence or absence of tetracycline or doxycycline by the method described above.
- Tertiary infection of step 2) can be carried out using the vector of the present invention comprising both TRAIL and CD genes in one vector.
- the TRAIL and CD genes may be made of respective gene constructs and inserted into two lentiviral vectors, respectively. That is, a lentiviral vector into which a gene construct prepared to express a gene encoding TRAIL protein is inserted and a lentiviral vector into which a gene construct prepared to express a gene encoding CD protein is expressed in a third infection. Can be used.
- the cells prepared by the method described above were named BM-03, and deposited on January 6, 2017, with the accession number KCTC 13182BP at the Korea Research Institute of Bioscience and Biotechnology.
- the present invention provides a pharmaceutical composition for preventing or treating cancer, comprising the recombinant lentiviral or host cell as described above as an active ingredient.
- the cancer refers to a general cancer including both blood cancer and solid cancer.
- Examples of cancer include gastric cancer, colon cancer, breast cancer, lung cancer, non-small cell lung cancer, bone cancer, pancreatic cancer, skin cancer, head or neck cancer, melanoma, uterine cancer, ovarian cancer, rectal cancer, endometrial cancer, Hodgkin's disease, brain tumor , Sarcoma cancer, esophageal cancer, small intestine cancer, thyroid cancer, prostate cancer, leukemia, lymphoma, bladder cancer, central nervous system tumors and spinal cord tumors.
- the pharmaceutical composition is a kind of cell therapy agent, and may further include a pharmaceutically acceptable carrier.
- the carrier is commonly used in the manufacture of drugs, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrroli Money, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil and the like.
- composition of the present invention may further include a pharmaceutically acceptable additive selected from the group consisting of lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives and combinations thereof.
- a pharmaceutically acceptable additive selected from the group consisting of lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives and combinations thereof.
- the carrier may comprise from about 1% to about 99.99% by weight, preferably from about 90% to about 99.99% by weight, based on the total weight of the pharmaceutical composition of the present invention, wherein the pharmaceutically acceptable additive is about 0.1 Weight percent to about 20 weight percent.
- the pharmaceutical composition may be prepared in unit dose form by formulating using a pharmaceutically acceptable carrier and excipient according to a conventional method, or may be prepared by incorporating into a multi-dose container.
- the formulation may be in the form of solutions, suspensions, syrups or emulsions in oils or aqueous media or in the form of extracts, powders, powders, granules, tablets or capsules, and may further comprise a dispersing or stabilizing agent.
- the present invention also provides a method of preventing or treating cancer as described above, comprising administering a pharmaceutical composition of the invention to a subject.
- the subject may be a mammal, specifically a human.
- the route of administration and dosage of the pharmaceutical composition can be administered to the subject in a variety of ways and amounts depending on the condition of the patient and the presence of side effects, and the optimal method of administration and dosage can be selected by the skilled person in the appropriate range.
- the pharmaceutical composition may be administered in combination with other drugs or physiologically active substances whose therapeutic effect is known for the disease to be treated, or may be formulated in combination with other drugs.
- examples thereof include subcutaneous, eye, intraperitoneal, intramuscular, oral, rectal, orbital, intracranial, intracranial, spinal, intraventricular, meninges, There is intranasal, intravenous administration.
- the administration may be administered one or more times, 1 to 3 times, and specifically, divided into two administrations. In the case of repeated administration, it may be administered at 12 to 48 hours and 24 to 36 hours, and specifically, at 24 hours.
- the lentiviral may be administered in an amount of 1.0x10 6 to 1.0x10 12 TU, specifically 1.0x10 8 to 1.0x10 10 TU, per adult day.
- the cells may be administered in an amount of 1.0x10 5 to 1.0x10 11 cells, specifically 1.0x10 7 to 1.0x10 9 cells per day of adult. If the dosage is high, it may be administered several times a day.
- lentiviral vectors containing immortalized genes c-Myc and hTERT, respectively, were prepared. At this time, the gene construct expressing the tTA protein was inserted together to use the Tet-off system.
- a pBD lentiviral vector was constructed by replacing an EF promoter with a CMV promoter in an expression cassette of a pWPT vector (Addgene, USA), and further connecting an RSV promoter to a lower portion thereof.
- c-Myc gene SEQ ID NO: 8
- TK thymidine kinase gene
- the hTERT gene (SEQ ID NO: 10) was inserted into the pBD lentiviral vector so that expression could be controlled by the CMV promoter.
- a gene ZeoR; SEQ ID NO: 16 having resistance to zeomycin was inserted so that expression could be regulated by the RSV promoter.
- the produced vector was named pBD-2.
- tTA tetracycline transactivator
- a lentiviral containing an immortalized gene was produced by the following method.
- Lenti-X cells (Clontech Laboratories, USA) were incubated in 150 mm dishes using DMEM medium containing 10% fetal calf serum.
- lentiviral vectors were extracted and quantified from DH5 ⁇ Escherichia coli cells using the EndoFree Plasmin Maxi Kit (Qiagen, USA).
- the cultured Lenti-X cells were washed with PBS and then 3 ml of TrypLE TM Select CTS TM (Gibco, USA) was added. After leaving the cells for about 5 minutes at 37 °C, it was confirmed that the cells detached. The detached cells were neutralized by adding DMEM medium containing 7 ml of 10% fetal calf serum. Neutralized cells were collected in 50 ml tubes and centrifuged at 1,500 rpm for 5 minutes. The supernatant was removed and cells were resuspended by adding DMEM culture medium containing 10 ml of 10% fetal calf serum.
- the suspended cells were counted with a hematocytometer and then aliquoted into 1.2 ⁇ 10 7 cells in a 150 mm dish.
- 12 ⁇ g lentiviral vector, 12 ⁇ g psPAX (Addgene; gag-pol expression, packaging plasmid) and 2.4 ⁇ g pMD.G plasmid (Addgene; VSVG Expression, envelope plasmid) mixture was transduced into the cells.
- lipofectamine Invitrogen, USA
- Plus Reagent Invitrogen, USA
- the obtained supernatant was mixed with a lentiviral enrichment kit (Lenti-X concentrator, Clontech Laboratories, USA) and then incubated overnight at 4 ° C. This was centrifuged for 2 hours at 4 ° C. and 4,000 rpm to obtain a virus, which was resuspended in 0.5 ml of DMEM without FBS. As a result, was placed in a pBD-1, pBD-2 and pBD-3 lentivirus vector
- the lentivirus virus respectively 4.0x10 8 TU / ml produced from a concentration of 2.0x10 8 TU / ml and 1.2x10 9 TU / ml.
- Immortalized MSCs were prepared using a lentivirus comprising an immortalized gene produced in Example 1-2 above.
- bone marrow-derived MSCs were prepared in the following manner. Specifically, bone marrow aspirate was obtained in the iliac crest of a healthy donor. This was mixed with 20 IU / ml heparin in a sterile container to inhibit coagulation. The bone marrow mixture was centrifuged at 4 ° C., 739 g for 7 minutes, then the supernatant was removed and mixed with 10-fold volume of sterile water. It was centrifuged again under the same conditions to obtain pellets of cells.
- the obtained pellet was suspended in DMEM-low glucose (11885-084, Gibco, USA) medium containing 20% FBS and 5 ng / ml b-FGF (100-18B, Peprotech, USA) and dispensed into culture flasks. It was. It was incubated for 24 to 48 hours at 37 ° C., 5% CO 2 conditions and then replaced with fresh medium. This was passaged while replacing with fresh medium at intervals of 3 to 4 days, and after 2 weeks of culture, MSC was checked using a fluorescence cell analyzer.
- the prepared MSCs with pBD-1 lentivirus produced in Example 1-2 were infected with 100 MOI using Retronectin (Retronectin, Clontech Laboratories, USA). Infected cells were infected in the same way with the pBD-2 lentiviral vector at 100 MOI. After infection, 500 ⁇ g / ml geomycin was added to the culture of stabilized cells to select cells infected with pBD-2 lentivirus.
- the selected cells were infected with pBD-3 lentiviral vector at 100 MOI. After infection, 1 ⁇ g / ml puromycin was added to the culture of stabilized cells to select cells infected with pBD-3 lentivirus.
- MSCs containing immortalized genes and MSCs not shown are shown in FIG. 1.
- MSC cells infected with lentiviral, including the immortalized genes c-myc and hTERT maintained a high cell proliferation rate even after 120 days of culture.
- normal MSC cells showed a rapid decrease in cell proliferation after 40 days of culture.
- TRAIL gene SEQ ID NO: 2
- CD gene SEQ ID NO: 4
- IRES internal ribosome entry site
- the produced vector was named pBD-4, and the structure of the gene construct is shown in FIG. 2.
- Lentiviruses were produced in the same manner as described in Example 1-2 above, using the lentiviral vectors comprising the TRAIL and CD genes prepared in Example 2-1.
- the lentiviral produced was prepared at a concentration of 7.6 ⁇ 10 8 TU / ml.
- the immortalized MSC prepared in Example 1-3 was infected with a lentiviral including the TRAIL and CD genes produced in Example 2-2 to prepare cells expressing TRAIL and CD genes. Infection was performed in the same manner as described in Examples 1-3. After infection, 1 ⁇ g / ml of doxycycline (631311, Clontech, USA) was added to the culture of stabilized cells, and cultured in a state of suppressing the expression of TRAIL and CD. After the cells stabilized, the cells were cultured for 72 hours in a culture medium without doxycycline to induce the expression of TRAIL and CD. The cells were subjected to FACS to select cells expressing TRAIL on the cell surface.
- doxycycline 631311, Clontech, USA
- lentiviral infected cells including TRAIL and CD genes were dispensed to 5 ⁇ 10 5 cells per FACS tube, which was centrifuged at 4 ° C. and 1,500 rpm for 5 minutes to remove supernatant. To this was added 1 ml of FACS buffer (PBS with 2% fetal bovine serum) to resuspend the cells and centrifuged under the same conditions to remove supernatant. After one more wash procedure, the cells were resuspended in 1 ml FACS buffer.
- FACS buffer PBS with 2% fetal bovine serum
- APC anti-human CD253 antibody BioLegend
- 0.3 ⁇ L of LIVE / DEAD ® Fixable Near-IR Dead Cell Stain (Life Technologies-Molecular Probes, USA) and 5 ⁇ l of anti-TRAIL antibody in 200 ⁇ l FACS buffer in resuspended cells , Cat #. 308210, USA) was added, and the mixture was reacted at 4 ° C for 30 minutes.
- the cells were washed twice in the same manner as above, and the supernatant was removed.
- To the washed cells was added 300 ⁇ l of fixing buffer (PBS with 2% formaldehyde and 1% fetal calf serum) and left at 4 ° C. for a minimum of 15 minutes.
- the cells were analyzed on a FACS (LSRFortessa, BD biosciences, USA) instrument to select cells expressing TRAIL.
- the selected cells were cultured to form colonies.
- Cell lines were established by culturing monoclonal cells from the colonies formed and named BM-03.
- the cell line BM-03 was deposited with KCTC 13182BP at the Korea Institute of Bioscience and Biotechnology as of January 6, 2017.
- the BM-03 cell line expresses the bone marrow of the surface antigen proteins CD90, CD44, CD105, and CD73, which are unique characteristics of MSC, even after genetic engineering to express TRAIL and CD therapeutic genes. Proved identical to the derived MSC.
- BM-03 cell lines were seeded in 12-well plates at a concentration of 1 ⁇ 10 4 cells / cm 2 to confirm adipogenesis. After incubation for 2 to 3 days at 37 °C, 5% CO 2 incubator using a normal medium, the adipogenic differentiation medium (StemPro® Adipogenic Differentiation Kit, Thermo fisher Scientific, A10070-01). The medium was changed every 3 to 4 days and incubated for 21 days. When the culture was completed, the oil red O solution staining (Oil Red O solution staining) was confirmed by a microscope.
- 12-well plates were seeded at a concentration of 5 ⁇ 10 3 cells / cm 2 . After incubation for 2 to 3 days at 37 °C, 5% CO 2 incubator using normal medium (StemPro®) Bone formation differentiation kit, Thermo fisher Scientific, A10072-01). The medium was changed every 3 to 4 days and incubated for 21 days. When the incubation was completed, Alizarin Red S staining was performed under a microscope.
- the suspension was suspended at a concentration of 1.6x10 7 cells / ml, and 5 ⁇ l of the seed was seeded in 24 wells and incubated for 2 hours.
- 500 ⁇ l of cartilage differentiation medium (StemPro® Cartilage Differentiation Kit, Thermo fisher Scientific, A10071-01) was added and then replaced at 3 day intervals and incubated for 14 days. After incubation, the medium was aspirated and rinsed with DPBS to remove the pellets. After cryosection, Alcian Blue staining was performed under a microscope. The results are shown in FIG.
- the BM-03 cell line was found to have multiple differentiation ability (transdifferentiation), which is a unique characteristic of MSC even after genetic manipulation to express TRAIL and CD therapeutic genes.
- the established cell line, BM-03 sample was thawed in a 37 ° C. water bath for about 1 minute, transferred to a 15 ml tube containing 9 ml PBS, and then celled down at 1,500 rpm for 5 minutes. After complete removal of PBS, pellets were transferred by suspension in 200 ⁇ l PBS in a 1.5 ml tube.
- GDNA was prepared using NucleoSpin® Tissue (MN, 740952.250) and a mixture was prepared as shown in Table 1, followed by PCR in the steps of Table 2 below. At this time, 100 ng of BM-03 plasmid DNA was added as a positive control and 1 ⁇ l dW was added as a negative control.
- BM-03 cell lines were seeded with 5 ⁇ 10 5 cells in a T75 flask using a medium containing 2 ⁇ g / ml of doxycycline in DMEM medium containing 10% FBS and no medium. Cells were obtained after incubation for 3 days. After measuring the number of cells, 5x10 5 cells in each group were stained with PE anti-human CD253 (TRAIL) antibody (BioLegend, 308206), PE Mouse IgG1, ⁇ Isotype Control Antibody (BioLegend, 400112). LIVE / DEAD® Fixable Near-IR Dead Cell Stain Kit (Thermos Fisher Scientific L34976) antibodies were also used to confirm expression after excluding dead cells.
- TRAIL PE anti-human CD253
- TRAIL was not expressed when doxycycline was added, but it was confirmed that TRAIL was expressed in the BM-03 cell line cultured in a medium in which doxycycline was removed.
- FIG. 7 it was found that when the CD protein is expressed, cells are killed by 5FC. That is, it was observed that cells were killed by expression of the CD protein. Therefore, TRAIL protein and CD protein are expressed in the prepared mesenchymal stem cells, it was confirmed that it is regulated by the Tet-off system.
- the BM-03 cell line was seeded using a medium containing 2 ⁇ g / ml of doxycycline in a T75 flask with 4 ⁇ 10 5 cell numbers. Cells were obtained by passage 3 or 4 days and the total cell number was measured. The same number of cells were seeded to measure PDL at 3-4 day intervals. PDL values were calculated using Equation 1 below, and the results are shown in FIG. 8. At this time, in Equation 1 below, X represents the initial PDL, I represents the initial cell number seeded in the blood vessel, Y represents the final cell yield, or the end cell growth.
- BM-03 cell line was analyzed according to a protocol specified by the Korea Institute of Biological Sciences (Korea). The analysis results are shown in FIG. 9.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Forward primer(서열번호 17) (10 pmol/㎕, GX535) | 1 ㎕ |
Reverse primer(서열번호 18) (10 pmol/㎕, GX534) | 1 ㎕ |
검체 (100 ng/㎕) | 1 ㎕ |
dW | 17 ㎕ |
Total volume | 20 ㎕ |
Step | Temperature | Time | Cycle |
1st | 95℃ | 5min | 1 |
2nd | 95℃ | 45sec | 35 |
58℃ | 45sec | ||
72℃ | 1min | ||
3rd | 72℃ | 7min | 1 |
4th | 4℃ | Indefinitely | 1 |
Claims (13)
- TNF-연관 세포사멸-유도 리간드 단백질(TRAIL), 및 시토신 디아미네이즈(CD) 단백질을 코딩하는 유전자를 포함하는 재조합 렌티바이러스 벡터.
- 제1항에 있어서,상기 TRAIL 단백질이 서열번호 1의 아미노산 서열을 갖는 폴리펩티드인, 재조합 렌티바이러스 벡터.
- 제1항에 있어서,상기 CD 단백질이 서열번호 3의 아미노산 서열을 갖는 폴리펩티드인, 재조합 렌티바이러스 벡터.
- 제1항에 있어서,상기 벡터가 1 또는 2개의 프로모터를 포함하는 것인, 재조합 렌티바이러스 벡터.
- 제4항에 있어서,상기 프로모터가 사이토메갈로바이러스(CMV), 호흡기세포융합바이러스(RSV), 인간 성장인자-1 알파(human elongation factor-1 alpha, EF-1α) 또는 TRE(tetracycline response elements) 프로모터인, 재조합 렌티바이러스 벡터.
- 제1항에 있어서,상기 벡터가 내부 리보솜 진입 부위(IRES)를 포함하는 것인, 재조합 렌티바이러스 벡터.
- TRAIL 단백질 및 CD 단백질을 코딩하는 유전자를 포함하는 재조합 렌티바이러스.
- 제7항에 있어서,상기 렌티바이러스는 제1항의 렌티바이러스 벡터, 패키징 플라스미드 및 엔벨로프 플라스미드로 숙주세포를 형질전환시키는 단계; 및형질전환된 숙주세포로부터 렌티바이러스를 분리하는 단계를 통하여 수득되는 것인, 재조합 렌티바이러스.
- 제7항의 재조합 렌티바이러스로 형질감염된 숙주세포.
- 제9항에 있어서,상기 숙주세포는 중간엽줄기세포인, 형질감염된 숙주세포.
- 제7항의 재조합 렌티바이러스를 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물.
- 제11항에 있어서,상기 암이 위암, 결장암, 유방암, 폐암, 비소세포성폐암, 골암, 췌장암, 피부암, 두부 또는 경부암, 흑색종, 자궁암, 난소암, 직장암, 자궁내막암, 호지킨병(Hodgkin's disease), 뇌종양, 육종암, 식도암, 소장암, 갑상선암, 전립선암, 백혈병, 림프종, 방광암, 중추신경계 종양 및 척수 종양으로 구성된 군으로부터 선택되는 것인, 약학 조성물.
- 제9항의 숙주세포를 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/075,380 US20190038676A1 (en) | 2016-02-05 | 2017-02-06 | Mesenchymal stem cell expressing trail and cd, and use thereof |
CN201780022188.1A CN109415740A (zh) | 2016-02-05 | 2017-02-06 | 表达trail和cd的间充质干细胞及其用途 |
CN202211091574.5A CN116064677A (zh) | 2016-02-05 | 2017-02-06 | 表达trail和cd的间充质干细胞及其用途 |
EP17747843.5A EP3412775A4 (en) | 2016-02-05 | 2017-02-06 | TRAIL AND DC EXPRESSIVE MESENCHYMIAL STEM CELL AND USE THEREOF |
JP2018560418A JP6725699B2 (ja) | 2016-02-05 | 2017-02-06 | Trailとcdを発現している間葉系幹細胞およびその使用 |
US17/853,259 US20220401491A1 (en) | 2016-02-05 | 2022-06-29 | Mesenchymal stem cell expressing trail and cd, and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20160015103 | 2016-02-05 | ||
KR10-2016-0015103 | 2016-02-05 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/075,380 A-371-Of-International US20190038676A1 (en) | 2016-02-05 | 2017-02-06 | Mesenchymal stem cell expressing trail and cd, and use thereof |
US17/853,259 Continuation US20220401491A1 (en) | 2016-02-05 | 2022-06-29 | Mesenchymal stem cell expressing trail and cd, and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017135800A1 true WO2017135800A1 (ko) | 2017-08-10 |
Family
ID=59499894
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2017/001308 WO2017135800A1 (ko) | 2016-02-05 | 2017-02-06 | Trail 및 cd를 발현하는 중간엽줄기세포 및 이의 용도 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20190038676A1 (ko) |
EP (1) | EP3412775A4 (ko) |
JP (1) | JP6725699B2 (ko) |
KR (1) | KR101985271B1 (ko) |
CN (2) | CN116064677A (ko) |
WO (1) | WO2017135800A1 (ko) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110669145A (zh) * | 2019-10-15 | 2020-01-10 | 北京贝来生物科技有限公司 | 三聚体trail融合蛋白基因修饰间充质干细胞的方法及其用途 |
WO2020045399A1 (ja) * | 2018-08-29 | 2020-03-05 | 株式会社Regene Pharm | がんの治療のための医薬組成物 |
JP2021511831A (ja) * | 2018-01-24 | 2021-05-13 | エスエルバイジェン インコ—ポレイテッドSlbigen Inc. | 脳由来神経栄養因子を発現する間葉系幹細胞およびその用途 |
EP3768842A4 (en) * | 2018-03-21 | 2021-12-29 | China Medical University | Engineering stem cells for cancer therapy |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4006145A4 (en) | 2019-07-24 | 2023-08-23 | Slbigen Inc. | PRODUCTION PROCESS OF AN IMPORTALIZED STEM CELL LINE AND ITS USE |
EP4032972A1 (en) * | 2019-09-18 | 2022-07-27 | Slbigen Inc. | Genetically modified nk cell line transduced with gene encoding novel chimeric antigen receptor and use thereof |
CN113073118B (zh) * | 2020-01-03 | 2023-09-15 | 珠海联邦制药股份有限公司 | Tet-off表达调控系统在级联放大启动子活性中的用途 |
CN113559123B (zh) * | 2021-08-06 | 2022-04-08 | 北京贝来生物科技有限公司 | 一种治疗白血病的联合用药物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5763223A (en) * | 1995-06-29 | 1998-06-09 | Immunex Corporation | DNA encoding a cytokine that induces apoptosis |
US6596533B1 (en) * | 1998-04-17 | 2003-07-22 | Transgene S.A. | Mutant having uracil phosphoribosyl transferase activity |
KR20130089214A (ko) * | 2012-02-01 | 2013-08-09 | 포항공과대학교 산학협력단 | 12량체 trail 및 hsv-tk 자살유전자를 동시에 발현하는 벡터 및 이를 이용한 항암 줄기세포 치료제 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130171115A1 (en) * | 2011-12-30 | 2013-07-04 | Gang Li | Cell-mediated gene therapy for cancer using mesenchymal stem cells expressing a suicide gene |
CN102965341B (zh) * | 2012-11-01 | 2014-12-10 | 中国疾病预防控制中心病毒病预防控制所 | 人脐带间充质干细胞系及其建立方法和应用 |
KR101585032B1 (ko) | 2015-04-30 | 2016-01-14 | (주)안트로젠 | 중간엽줄기세포-하이드로겔을 함유하는 조성물 및 이의 제조방법 |
-
2017
- 2017-02-06 JP JP2018560418A patent/JP6725699B2/ja active Active
- 2017-02-06 WO PCT/KR2017/001308 patent/WO2017135800A1/ko active Application Filing
- 2017-02-06 KR KR1020170016351A patent/KR101985271B1/ko active IP Right Grant
- 2017-02-06 EP EP17747843.5A patent/EP3412775A4/en active Pending
- 2017-02-06 CN CN202211091574.5A patent/CN116064677A/zh active Pending
- 2017-02-06 US US16/075,380 patent/US20190038676A1/en not_active Abandoned
- 2017-02-06 CN CN201780022188.1A patent/CN109415740A/zh active Pending
-
2022
- 2022-06-29 US US17/853,259 patent/US20220401491A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5763223A (en) * | 1995-06-29 | 1998-06-09 | Immunex Corporation | DNA encoding a cytokine that induces apoptosis |
US6596533B1 (en) * | 1998-04-17 | 2003-07-22 | Transgene S.A. | Mutant having uracil phosphoribosyl transferase activity |
KR20130089214A (ko) * | 2012-02-01 | 2013-08-09 | 포항공과대학교 산학협력단 | 12량체 trail 및 hsv-tk 자살유전자를 동시에 발현하는 벡터 및 이를 이용한 항암 줄기세포 치료제 |
Non-Patent Citations (2)
Title |
---|
WEI ET AL.: "Cytosine Deaminase/5-fluorocytosine Gene Therapy and Apo2L/TRAIL Cooperate to Kill TRAIL-resistant Tumor Cells", CANCER GENE THERAPY, vol. 14, 2007, pages 640 - 651, XP055406265 * |
WENGER ET AL.: "Specific Resistance upon Lentiviral TRAIL Transfer by Intracellular Retention of TRAIL Receptors", CELL DEATH & DIFFERENTIATION, vol. 13, 2006, pages 1740 - 1751, XP055406264 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021511831A (ja) * | 2018-01-24 | 2021-05-13 | エスエルバイジェン インコ—ポレイテッドSlbigen Inc. | 脳由来神経栄養因子を発現する間葉系幹細胞およびその用途 |
JP7016556B2 (ja) | 2018-01-24 | 2022-02-07 | エスエルバイジェン インコ―ポレイテッド | 脳由来神経栄養因子を発現する間葉系幹細胞およびその用途 |
EP3768842A4 (en) * | 2018-03-21 | 2021-12-29 | China Medical University | Engineering stem cells for cancer therapy |
US11458171B2 (en) | 2018-03-21 | 2022-10-04 | China Medical University | Engineering stem cells for cancer therapy |
WO2020045399A1 (ja) * | 2018-08-29 | 2020-03-05 | 株式会社Regene Pharm | がんの治療のための医薬組成物 |
CN110669145A (zh) * | 2019-10-15 | 2020-01-10 | 北京贝来生物科技有限公司 | 三聚体trail融合蛋白基因修饰间充质干细胞的方法及其用途 |
CN110669145B (zh) * | 2019-10-15 | 2021-08-27 | 北京贝来生物科技有限公司 | 三聚体trail融合蛋白基因修饰间充质干细胞的方法及其用途 |
Also Published As
Publication number | Publication date |
---|---|
CN116064677A (zh) | 2023-05-05 |
JP2019504644A (ja) | 2019-02-21 |
EP3412775A1 (en) | 2018-12-12 |
KR20170093748A (ko) | 2017-08-16 |
KR101985271B1 (ko) | 2019-06-04 |
CN109415740A (zh) | 2019-03-01 |
US20220401491A1 (en) | 2022-12-22 |
EP3412775A4 (en) | 2019-07-31 |
JP6725699B2 (ja) | 2020-07-22 |
US20190038676A1 (en) | 2019-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017135800A1 (ko) | Trail 및 cd를 발현하는 중간엽줄기세포 및 이의 용도 | |
WO2017135795A1 (ko) | 간세포성장인자를 발현하는 중간엽줄기세포 및 이의 용도 | |
Ernst et al. | Functional and biochemical association of Hck with the LIF/IL‐6 receptor signal transducing subunit gp130 in embryonic stem cells. | |
WO2020197318A1 (ko) | Car 유전자가 도입된 nk 세포의 제조방법 및 그의 용도 | |
KR102427892B1 (ko) | 뇌유래-신경영양인자를 발현하는 중간엽줄기세포 및 이의 용도 | |
KR102427786B1 (ko) | 엑소좀 생산 조절 세포, 이를 포함하는 조성물, 이로부터 얻은 엑소좀 및 엑소좀 생산 방법 | |
WO2012047037A2 (ko) | 배아줄기세포 유래 심근세포 및 이를 유효성분으로 포함하는 세포치료제 | |
WO2019216667A1 (ko) | Sox2, c-Myc를 이용하여 비신경 세포로부터 직접 리프로그래밍된 유도신경줄기세포를 제조하는 방법 | |
WO2021034157A1 (ko) | 암세포 표적화 영역과 hvem의 세포외 도메인의 융합 단백질을 발현할 수 있는 발현 카세트를 가지는 재조합 헤르페스 심플렉스 바이러스 및 그 용도 | |
KR20220137882A (ko) | 보편적 세포 요법을 위한 면역 회피 기작의 조절제 | |
WO2016117960A1 (ko) | 면역질환 치료 효능을 갖는 grim19이 과발현된 중간엽줄기세포 및 이의 용도 | |
WO2022158800A1 (ko) | 면역세포 관용성 조절인자 과발현 줄기세포 및 이의 용도 | |
KR20190015154A (ko) | Trail 및 cd를 발현하는 중간엽줄기세포를 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물 | |
WO2021015584A1 (ko) | 불사화된 줄기세포주의 제조 방법 및 이의 용도 | |
KR20110090810A (ko) | 노치 신호 활성 유전자를 이용한 줄기세포의 증식 방법 | |
KR20230043906A (ko) | 영양 장애형 표피 수포증의 치료약 | |
WO2022010220A1 (ko) | 면역원성이 감소된 신규한 이식용 세포 | |
WO2019235771A1 (ko) | 아데노바이러스의 감염 및 복제가 가능한 중간엽 줄기세포주 | |
KR20210116172A (ko) | 인간 지방 유래 성체 줄기세포를 이용한 렌티바이러스 벡터 및 항암제 조성물 | |
KR20230010597A (ko) | 트랜스포존 시스템 및 이의 용도 | |
JP2009159868A (ja) | 造血幹細胞の維持・増幅方法 | |
WO2008091680A2 (en) | Methods for controlling stem cell differentiation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17747843 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2018560418 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017747843 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2017747843 Country of ref document: EP Effective date: 20180905 |